About Event

Welcome to the Cytokine-Based Cancer Immunotherapies Summit Boston

The therapeutic opportunities presented by the synergistic effect of T-cell based immunotherapies and cytokine-based interventions is well documented in pre-clinical models. However, due to systemic toxicity and the lack of durable efficacy responses (in lower doses) in clinical trials, drug developers are faced with the challenges of how to expand the therapeutic index of cytokine-based cancer immunotherapies. This summit focuses on the raw challenges holding back the space: how the leaders in the field are addressing barriers in the toxicity, dosage, delivery, specificity, combinatorial and translational issues which are driving investment and resources in this space.

imageedit_4_4883615109

Delve into cytokine research beyond oncology, understand application & translation in inflammatory diseases with AbbVie & University of Dundee

imageedit_4_4883615109

Uncover the therapeutic potential of cytokines through methods of overcoming toxicity with Merck & Co. , John Hopkins, TeneoBio & Xilio Therapeutics

imageedit_4_4883615109

Optimize application through successful cytokine dosing & delivery with Philogen, MD Anderson & Ankyra Therapeutics

imageedit_4_4883615109

Discover the clinical results & what these mean for the translatability of pre-clinical data and the future of this space with Roche, Sanofi & BioNTech

imageedit_4_4883615109

Network In Person with all attendees, ask your burning questions, build connections and fully immerse yourself in the world of cytokines

Companies Who Attended in March

Cytokine Companies attending (2)